Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL.

Science. 2001 Aug 3;293(5531):876-80. Epub 2001 Jun 21.

2.

Cancer research. Why some leukemia cells resist STI-571.

Marx J.

Science. 2001 Jun 22;292(5525):2231-3. No abstract available.

PMID:
11423629
3.

Roots of clinical resistance to STI-571 cancer therapy.

Barthe C, Cony-Makhoul P, Melo JV, Mahon JR.

Science. 2001 Sep 21;293(5538):2163. No abstract available.

4.

Roots of clinical resistance to STI-571 cancer therapy.

Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R, Gambacorti- Passerini C, Corneo G, D'Incalci M.

Science. 2001 Sep 21;293(5538):2163. No abstract available.

PMID:
11569495
5.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

6.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ.

Curr Opin Hematol. 2004 Jan;11(1):35-43. Review.

PMID:
14676625
7.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

8.

Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.

Chien JH, Tang JL, Chen RL, Li CC, Lee CP.

Leuk Res. 2008 Nov;32(11):1724-34. doi: 10.1016/j.leukres.2008.04.023. Epub 2008 Jul 7.

PMID:
18603297
9.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
10.
11.

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.

Sacha T, Hochhaus A, Hanfstein B, Müller MC, Rudzki Z, Czopek J, Wolska-Smoleń T, Czekalska S, Salamanchuk Z, Jakóbczyk M, Skotnicki AB.

Leuk Res. 2003 Dec;27(12):1163-6.

PMID:
12921956
12.

New-age drug meets resistance.

McCormick F.

Nature. 2001 Jul 19;412(6844):281-2. No abstract available.

PMID:
11460142
13.

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.

Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD.

Eur J Haematol. 2003 Apr;70(4):235-9.

PMID:
12656747
14.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX.

Br J Haematol. 2002 Oct;119(1):109-11.

PMID:
12358910
15.

Resistance in the land of molecular cancer therapeutics.

Shannon KM.

Cancer Cell. 2002 Aug;2(2):99-102. Review.

16.
17.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.

Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.

18.

Cytogenetic and molecular mechanisms of resistance to imatinib.

Hochhaus A.

Semin Hematol. 2003 Apr;40(2 Suppl 2):69-79.

PMID:
12783379
19.

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.

Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M.

Cancer Res. 2002 Nov 1;62(21):5995-8.

20.

Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.

Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.

Stem Cells. 2003;21(3):315-21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk